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1. Introduction 
In 1985, 3’-azido-thymidine (AZT, zidovudine) was identified as the first nucleoside analog 
with activity against human immunodeficiency virus type 1 (HIV-1) (Mitsuya et al., 1985, 1987; 
Mitsuya & Broder, 1986), the etiologic agent of acquired immunodeficiency syndrome (Barre-
Sinoussi et al., 1983; Gallo et al., 1984). This seminal discovery showed that HIV-1 replication 
could be suppressed by small molecule chemotherapeutic agents, and provided the basis for 
the field of antiviral drug discovery. Zidovudine was approved by the United States of 
America Food and Drug Administration for the treatment of HIV-1 infection in 1987. In the 26 
years since, an additional seven nucleoside or nucleotide analogs have been approved, while 
several others are in clinical development. This chapter will provide a summary of the 
molecular pharmacology of these compounds. 
2. Mechanism of action 
Retroviruses such as HIV-1 carry their genomic information in the form of (+)strand RNA, 
but are distinguished from other RNA viruses by the fact that they replicate through a 
double-stranded DNA that is integrated into the host cell’s genomic DNA (Temin & 
Mizutani, 1970; Baltimore, 1970; DeStefano et al., 1993). While the conversion of viral RNA 
into double-stranded DNA intermediate is a complex process, all chemical steps are 
catalyzed by the multi-functional viral enzyme reverse transcriptase (RT). HIV-1 RT exhibits 
two types of DNA polymerase activity, an RNA-dependent DNA polymerase activity that 
synthesizes a (-)strand DNA copy of the viral RNA, and a DNA-dependent DNA 
polymerase activity that generates the (+)strand DNA (Peliska & Benkovic, 1992; Cirno et 
al., 1995). RT also has ribonuclease H activity that degrades the RNA in the intermediate 
(+)RNA/(-)DNA duplex (Ghosh et al., 1997).  
Once metabolized by host cell enzymes to their triphosphate forms (described in more detail 
below), nucleoside analogs inhibit HIV-1 reverse transcription. As such, they are typically 
referred to as nucleoside RT inhibitors (NRTI).  NRTI-triphosphates (NRTI-TP) inhibit RT-
catalyzed proviral DNA synthesis by two mechanisms (Goody et al., 1991). First, they are 
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competitive inhibitors for binding and/or catalytic incorporation with respect to the 
analogous natural dNTP substrate. Second, they terminate further viral DNA synthesis due 
to the lack of a 3’-OH group. Chain termination is the principal mechanism of NRTI 
antiviral action (Goody et al., 1991). In theory, NRTI-TPs should be ideal antivirals. Each 
HIV virion carries only two copies of genomic RNA. There are about 20,000 nucleotide 
incorporation events catalyzed by RT during the synthesis of complete viral DNA, thus 
providing about 5000 chances for chain-termination by any given NRTI. Since HIV-1 RT 
lacks a formal proof-reading activity, a single NRTI incorporation event should effectively 
terminate reverse transcription. In reality, however, NRTIs are less potent than might be 
expected. The two primary reasons responsible for this are: (i) HIV-1 RT can effectively 
discriminate between the natural dNTP and NRTI-TP, and the extent of this discrimination 
is dramatically modulated by nucleic acid sequence (Isel et al., 2001); and (ii) HIV-1 RT can 
excise the chain-terminating NRTI-monophosphate (NRTI-MP) by using either 
pyrophosphate (pyrophophorolysis) or ATP as a substrate (Meyer et al., 1998; Goldschmidt 
& Marquet, 2004).   
3. NRTI approved for clinical use 
3.1 Zidovudine 
Zidovudine was first synthesized in 1964 as a potential anticancer drug, but was not further 
developed for human use because of toxicity concerns. However, as described in the 
Introduction, it was found to have potent anti-HIV activity and, in 1987, was the first 
antiviral drug to be approved for clinical use. Zidovudine is a thymidine analog in which 
the 3’-OH group has been replaced with an azido (-N3) group (Figure 1). Zidovudine 
permeates the cell membrane by passive transport and not via a nucleoside carrier 
transporter (Zimmerman et al., 1987). It has good oral bioavailability and shows efficient 
penetration into the central nervous system. Zidovudine is efficiently metabolized to its 5’-
MP form by cytosolic thymidine kinase (Ho & Hitchcock, 1989). The phosphorylation of 
zidovudine-MP to zidovudine-DP is catalyzed by thymidinylate monophosphate kinase 
(dTMP kinase; Furman et al., 1986). Interestingly, the apparent Michaelis constant (Km) of 
zidovudine-MP for dTMP kinase is almost equivalent to that of dTMP, however its 
maximum kinetic rate (Vmax) is only 0.3 % that of dTMP (Furman et al., 1986). Therefore, 
zidovudine-MP acts as a substrate inhibitor of dTMP kinase and limits its own conversion to 
the 5'-DP form. In this regard, there is a marked accumulation of zidovudine-MP and only 
low levels of the 5'-DP- and 5'-TP derivatives are detected in human T-lymphocytes 
(Balzarini et al., 1989). Cellular nucleoside diphosphate kinase (NDP kinase) is likely 
responsible for the further conversion of zidovudine-DP to zidovudine-TP. Zidovudine is 
metabolized to its 5’-O-glucuronide in the liver, kidney, and intestinal mucosa (Barbier et al., 
2000). Because of the extensive glucuronidation of ZDV, other drugs that are also 
glucuronidated or that inhibit this process cause an increase in zidovudine plasma levels. 
Fourteen percent of the parent compound and 74% of the glucuronide have been recovered 
from the urine after oral administration in normal subjects (Ruane et al., 2004). Renal 
excretion of zidovudine is by both glomerular filtration and active tubular secretion. In 
some cells zidovudine can be metabolized to the highly toxic reduction product 3’-amino-
thymidine (Weidner & Sommadossi, 1990). 
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3.2 Stavudine 
Like zidovudine, stavudine (2’,3’-didehydro-3’-deoxythymidine, d4T) is a thymidine analog 
that undergoes metabolic activation by the sequential action of thymidine kinase and dTMP 
kinase (Figure 1). However, stavudine is inefficiently phosphorylated to its 5’-MP form by 
thymidine kinase (August et al., 1988; Zhu et al., 1990). As such, this first phosphorylation 
step is rate-limiting and most intracellular stavudine is not phophorylated (Balzarini et al., 
1989). Maximal plasma concentrations of stavudine are achieved within 2 hours of oral 
administration and increase linearly as the dose increases, with an absolute bioavailability 
approaching 100 % (Rana & Dudley, 1997)). The drug distributes into total body water and 
appears to enter cells by non-facilitated diffusion (passive transport). Penetration into the 
central nervous system, however, is far less than zidovudine. Stavudine is cleared quickly 
with a terminal plasma half-life of 1-1.6 hours by both renal and nonrenal processes (Dudley 
et al., 1992). 
 
Fig. 1. Metabolic pathways of zidovudine and stavudine 
3.3 Didanosine 
Initially, 2’,3’-dideoxyadenosine (ddA) was evaluated as a clinical candidate but was 
ultimately discovered to cause nephrotoxicity. ddA is acid labile and oral administration leads 
to exposure to the acidic pH of the stomach and degradation to adenine (Masood et al., 1990). 
Adenine is further metabolized to 2,8-dihydroxyadenine which causes nephrotoxicity by 
crystallization in the kidney. Interestingly, ddA was shown to be metabolized to 2’,3’-
dideoxyinosine (ddI, didanosine) by adenosine deaminase (Figure 2), and that much of the 
antiviral activity of ddA resides in didanosine (Cooney et al., 1987). Furthermore, the 
administration of didanosine avoids the production of adenine and the resulting 
nephrotoxicity. Didanosine is phosphorylated to didanosine-MP by cytosolic 5'-nucleotidase, 
which uses either inosine monophosphate (IMP) or guanosine monophosphate (GMP) as 
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phosphate donors (Johnson & Fridland, 1989). Didanosine-MP is then converted to ddAMP by 
adenylosuccinate synthetase and 5' adenosine monophosphate-activated protein (AMP) kinase 
(Ahluwalia et al., 1987). The enzymes involved in phosphorylation of ddAMP to ddADP and 
ddATP have not been identified, although AMP kinase and NDP kinase have been proposed 
to play a role. ddATP is the active metabolite that is recognized by HIV-1 RT and incorporated 
into the nascent viral DNA chain causing chain-termination. No evidence has been provided 
for the formation of didanosine-DP or didanosine-TP. Didanosine is hydrolyzed to 
hypoxanthine by purine nucleoside phosphorylase (PNP) and further anabolized by 
hypoxanthine-guanine phosphoribosyl transferase to IMP (Ahluwalia et al., 1987). ATP and 
GTP are formed from IMP through the classical purine nucleotide biosynthetic pathways.  
 
Fig. 2. Metabolic pathways of ddA and didanosine 
3.4 Lamivudine and emtricitabine  
The structurally related cytidine analogs lamivudine ((-)-3’-thia-2’,3’-dideoxycytidine;  3TC) 
and ematricitabine ((-)-3’-thia-5-flouro-2’,3’-dideoxycytidine;  FTC)  both contain the 
unnatural L-enantiomer ribose with a sulfur atom replacing the C3’ position (Figure 3). 
Emtricitabine has an additional 5-flouro moiety on the cytosine ring. Lamivudine and 
emtricitabine are both metabolized to their respective 5'-mono- and di- and triphosphate 
derivatives by deoxycytidine kinase, deoxycytidine monophosphate kinase, and 5’-
nucleoside diphosphate kinase, respectively (Chang et al., 1992; Cammack et al., 1992; Stein 
& Moore 2001; Darque et al., 1999; Bang & Scott, 2003). There is no evidence that lamivudine 
or emtricitabine are deaminated to their uridine analogs by cellular cytidine or 
deoxycytidine deaminases (Starnes & Cheng, 1987). Formation of the free base by cellular 
pyrimidine phosphorylases has also not been observed. Lamivudine-DP and emtricitabine-
TP accumulate to higher levels in peripheral blood mononuclear cells than their 
monophosphate forms. It has been suggested that conversion of lamivudine-DP to 
lamivudine-TP is rate limiting. Lamivudine and emtricitabine are rapidly absorbed through 
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the GI tract with peek plasma levels of 85-93% achieved within 2 hours post oral 
administration. Lamivudine has a plasma half-life of 5-7 hours and is eliminated 
unmetabolized by active organic cationic excretion (Johnson et al., 1999). Emtricitabine 
persists in plasma with a half-life of 10 hours and is eliminated primarily in urine by 
glomerular filtration and active tubular secretion but approximately 14% is eliminated in 
feces. Oxidation of the 3’-thiol by unidentified enzymes yields 3’-sulfoxide diasteriomers 
and 2’-O-glucuronidation also occurs. 
 
Fig. 3. Metabolic pathways of lamivudine and emtricitabine 
3.5 Abacavir 
Abacavir (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol) 
is a prodrug of carbovir (2-Amino-1,9-dihydro-9-[(1R,4S)-4-(hydroxymethyl)-2-cyclopenten-
1-yl]-6H-purin-6-one), a deoxyguanosine analog (Figure 4; Daluge et al., 1997). Abacavir 
permeates T lymophoblastoid cell lines by passive diffusion. Abacavir is phosphorylated to 
abacavir-MP by adenosine phosphotransferase (Faletto et al., 1997). A yet unidentified 
cytosolic deaminase then converts abacavir-MP to carbovir-MP. Phosphorylation to the 
diphosphate derivative occurs via guanidinylate monophosphate kinase. The final 
phosphorylation step can be catalyzed by a number of cellular enzymes including 5’-
nucleotide diphosphate kinase, pyruvate kinase, and creatine kinase (Faletto et al., 1997). A 
linear dose relationship with carbovir-mono-, di-, and tri- phosphate derivatives over a 
1000-fold dose range in vitro suggests there are no rate limiting steps in abacavir anabolism. 
The active metabolite carbovir-TP has been shown to persist with an elimination half-life of 
greater than 20 hours (McDowell et al., 2000). Abacavir bioavailability is ~83 % and is 
rapidly absorbed after oral dosing reaching peak plasma levels within 1 hour (Chittick et al., 
1999). However, abacavir is extensively catabolized in the liver and only 1.2% is excreted as 
unchanged abacavir in urine. Abacavir oxidation by alcohol dehyrogenases to form the 5’-
carboxylic acid derivative represents 36% of metabolites recovered from urine, while the 5’-
O-glucuronide corresponds to 30% of metabolites from urine (Chittick et al., 1999). Fecal 
excretion also accounts for approximately 16 % of the given dose. Abacavir is not 
metabolized by cytochrome P450 enzymes and does not inhibit these enzymes.  
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Fig. 4. Metabolic pathways for abacavir 
3.6 Tenofovir and tenofovir disoproxil fumerate 
The acyclic nucleoside phosphonate tenofovir (R-9-(2-phosphonylmethoxypropyl)-adenine) 
has no sugar ring structure but contains an acyclic methoxypropyl linker between the base 
N9 atom and a non-hydrolyzable C-P phosphonate bond. Thus tenofovir represents the only 
currently approved nucleotide HIV inhibitor. Tenofovir is poorly absorbed by the oral route 
and is therefore administered as a lipophilic orally bioavailable prodrug tenofovir disoproxil 
fumerate (TDF), a fumaric acid salt of the bis-isopropoxycarbonyloxymethyl ester of 
tenofovir (Figure 5). TDF is readily absorbed by the gastrointestinal epithelial cells with an 
oral bioavailability of 25% (Barditch-Crovo et al., 2001). Administration with a high fat meal 
increases absorption to 40%. Degradation of TDF to its monoester and subsequently to 
tenofovir occurs readily in the intestinal mucosa by the action of carboxylesterases and 
phosphodiesterases, respectively. The mono- or bis-ester forms of tenofovir are not observed 
in plasma suggesting efficient release of tenofovir following oral administration of TDF 
(Naesens et al., 1998). Following oral administration tenofovir has a long terminal half-life of 
17 hours. The phosphonic acid linkage is chemically and metabolically stable and 
phosphorolysis back to the nucleoside does not occur (Naesens et al., 1998). Tenofovir is 
rapidly converted intracellularly to tenofovir-monophosphate and the active tenofovir-
diphosphate forms by adenylate monophosphate kinase and 5’-nucleoside diphosphate 
kinase, respectively (Robbins et al., 1998). Tenofovir is not subject to intracellular 
deamination or deglycosylation. This stability results in a very long intracellular half-life for 
tenofovir-diphosphate of 15 hours in activated lymphocytes and 50 hours in resting 
lymphocytes (Robbins et al., 1998). Tenofovir is eliminated by glomerular filtration and 
active tubular secretion by organic anion transporter mediated uptake and MRP4 mediated 
efflux (Ray et al., 2006). At 72 hours post oral administration 70 - 80 % is recovered from 
urine as unchanged tenofovir. Tenofovir does not inhibit cytochrome P450 enzymes. 
glucuronosyltransferase 
www.intechopen.com
 Molecular Pharmacology of Nucleoside and Nucleotide HIV-1 Reverse Transcriptase Inhibitors 69 
However, the mono- and di-phosphate forms both inhibit purine nucleoside phosphorylase 
which is responsible for base removal of didanosine to form hypoxanthine. 
 
Fig. 5. Metabolic pathways of tenofovir and TDF 
4. NRTI in the pipeline 
Despite the widespread clinical success of NRTI-containing therapy, the currently FDA 
approved NRTIs display important limitations including the selection of drug resistance 
mutations that display cross-resistance to other NRTI, toxicity-related adverse events, and 
drug-drug interactions (for review see Cihlar & Ray, 2010). Thus, there is a need for novel 
NRTI that overcome these limitations. Here we will discuss the pharmacology of several 
novel drug candidates. 
4.1 Apricitabine  
Apricitabine (ATC) is the (-)-enantiomer of 2’-deoxy-3’-oxa-4’-thiocytidine, a deoxycytidine 
analog that is currently in phase II/III clinical trials (Figure 6). Both the (+) and (-)-
enantiomers of apricitabine demonstrate potent inhibition of HIV-1 replication, however the 
(+)-enantiomer demonstrated significant mitochondrial and cellular toxicity in pre-clinical 
studies that was not observed with the (-) enantiomer (de Muys et al., 1999; Taylor et al., 
2000). Racemic conversion of (-)-apricitabine to (+)-apricitabine is not observed in vivo 
(Holdich et al., 2006). Orally administered ATC is absorbed quickly, reaching maximal 
plasma levels within 2 hours with a plasma half-life of 3 hours. Maximal peripheral blood 
mononuclear cell (PBMC) intracellular concentrations of apricitabine -TP are achieved 3.5 – 
4 hours after oral administration in healthy and HIV-infected patients. The intracellular half-
life is  6 – 7 hours (Sawyer & Struthers-Semple, 2006; Cahn et al., 2008; Holdich et al., 2007). 
Apricitabine is not metabolized by hepatocytes in vitro, however a deaminated metabolite 
was observed likely due to gastrointestinal metabolism (Nakatani-Freshwater et al., 2006). 
This metabolite is excreted renally and does not demonstrate antiviral or pharmacologic 
effects. Apricitabine had no effect on cytochrome P450 or glucouronidase but was a weak 
inhibitor of P-glycoprotein (Sawyer & Cox, 2006). The first phosphorylation of apricitabine is 
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mediated by deoxycytidine kinase, the enzyme also responsible for the initial 
phosphorylation of lamivudine and emtricitabine (de Muys et al., 1999). The possibility of 
competition for deoxycytidine kinase was examined in PBMC. Co-administration of 
apricitabine with lamivudine or emtricitabine leads to a dose-dependent decrease in 
apricitabine phosphorylation, whereas lamivudine and emtricitabine phosphorylation was 
not affected by apricitabine (Bethell et al., 2007). In healthy volunteers given apricitabine 
and lamivudine, the intracellular PBMC levels of apricitabine-TP were decreased 75% 
compared to apricitabine alone (Holdich et al., 2006). Consequently, administration of 
apricitabine in combination with lamivudine or emtricitabine is not recommended. 
Similarly, lamivudine and emtricitabine co-administration is also contraindicated. 
Apricitabine-MP is sequentially phosphorylated to the di- and tri-phosphate forms by 
cytidine or deoxycytidine monophosphate kinase and 5’-nucleotide diphosphate kinase, 
respectively. 
 
Fig. 6. Metabolic pathway of apricitabine 
4.2 Festinavir  
Festinavir (2’,3’-didehydro-3’-deoxy-4’-ethynylthymidine; 4’-Ed4T) is a 4’-ethynyl analog of 
stavudine that is 5-10 fold more potent (Figure 7) (Haraguchi et al., 2003; Nitanda et al., 
2005). Festinavir shows decreased cellular toxicity compared to stavudine, with little or no 
inhibition of host polymerases (Yang et al., 2007; Dutschman et al., 2004). Stepwise 
phosphorylation of festinavir occurs via the same enzymes as stavudine. Thymidine kinase 
1 phosphorylates festinavir to festinavir-MP with 4-fold greater efficiency than stavudine 
(Hsu et al., 2007). The efficiency of festinavir-MP phosphorylation by thymidinylate 
monophosphate kinase is approximately 10 % of that seen for stavudine-MP or zidovudine-
MP. Conversion from festinavir-DP to festinavir-TP appears to be catalyzed by multiple 
enzymes including nucleoside diphosphate kinase, pyruvate kinase, creatine kinase, and 3-
phosphoglycerate kinase (Hsu et al., 2007). In contrast to other thymidine analogs which are 
readily catabolized by thymidine phosphorylase, festinavir catabolism cannot be detected. 
Furthermore, festinavir efflux from the cell is much less efficient than that of zidovudine. 
The festinavir nucleoside form alone is effluxed by a yet to be identified cellular transporter, 
while zidovudine and zidovudine-MP are effluxed from the cell. A Phase 1a study 
investigated the pharmacokinetic profile of a single oral dose between 10 and 900 mg and 
found a linear dose response in plasma with no apparent effects from food (Paintsil et al., 
2009). A Phase 1b/2a study of festinavir oral  monotherapy in 32 patients was recently 
completed. The results indicated that festinavir was safe (few festinavir related adverse 
events), well tolerated, and demonstrated dose dependent decreases in viral load between 
0.87 and 1.36 logs (Cotte et al., 2010). 
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Fig. 7. Metabolic pathway of festinavir 
4.3 Amdoxovir 
The purine nucleoside analog 1-β-D-dioxolane guanosine (DXG) has potent activity against 
HIV and hepatitis B virus (Kim et al., 1993). However, it demonstrates poor solubility and 
limited oral bioavailability in monkeys (Chen et al., 1996). The analog 1-β-D-2,6-
diaminopurine dioxolane (amdoxovir; Figure 8) also exhibits antiviral activity and is more 
water soluble and orally bioavailable (Chen et al., 1999; Kim et al., 1993)). Amdoxovir serves 
as a prodrug for DXG by deamination at the 6-position by adenosine deaminase (Gu et al., 
1999). In vitro, amdoxovir bound adenosine deaminase as efficiently as adenosine, however 
amdoxovir was deaminated 540-fold slower than adenosine (Furman et al., 2001). Only 
DXG-triphosphate was detected in PBMC and CEM cells following exposure to DXG or 
amdoxovir (Rajagopalan et al., 1994; Rajagopalan et al., 1996). DXG is phosphorylated to 
DXG-MP by 5’-nucleotidase using IMP as a phosphate donor (Feng et al., 2004). DXG-
diphosphate is then generated by guanosine monophosphate kinase (GMP kinase). DXG-DP 
acts as substrate for phosphorylation to the active DXG-TP for several enzymes including 
nucleotide diphosphate kinase (NDP kinase), 3-phosphoglycerate kinase (3-PG kinase, 
creatine kinase, and pyruvate kinase. Amdoxovir is rapidly converted to DXG in monkeys, 
 
Fig. 8. Metabolic pathway of amdoxovir 
woodchucks, and rats with approximately 61 % of the dose converted to DXG (Chen et al., 
1996; Chen et al., 1999; Rajagopalan et al., 1996). The oral bioavailability of amdoxovir is 
estimated to be 30% (Chen et al., 1999). Following oral administration of amdoxovir to HIV-
infected patients, peak plasma levels of amdoxivir and DXG were reached within 2 hours 
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(Thompson et al., 2005). Amdoxovir was eliminated from plasma with half-life of 1 - 2 hours 
by conversion to DXG, whereas DXG demonstrated a longer half-life of 4 - 7 hours. In 
animal studies amdoxovir toxicities included obstructive nephropathy, uremia, islet cell 
atrophy, hyperglycemia, and lens opacities (Rajagopalan et al., 1996). In a phase I/II clinical 
study 4 of 18 patients developed nongradeable lens opacities (Thompson et al., 2005). In 
other studies most adverse events were minor and included nausea, headache, and diarrhea 
(Gripshover et al., 2006; Murphy et al., 2008). 
4.4 GS-7340  
GS-7340 (9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]-
methoxy]propyl]adenine) is a novel isopropylalaninyl phenyl ester prodrug of tenofovir 
designed to increase intracellular delivery of the active tenofovir-DP metabolite by masking 
the charged phosphonate (Figure 9; Eisenberg et al 2001). Preclinical studies demonstrated 
200-fold improved plasma stability and 400-fold increased accumulation of tenofovir and 
active tenofovir-DP in lymphatic tissues and peripheral blood mononuclear cells (PBMC) 
compared to tenofovir (Lee et al., 2005; Eisenberg et al., 2001). GS-7340 has 1000-fold 
improved potency in vitro over tenofovir. Following rapid target cell uptake, GS-7340 is 
hydrolyzed at the carboxy ester bond in lysozomes by the serine protease cathepsin A and 
other serine and cysteine proteases (Birkus et al., 2007; 2008). The resulting partially stable 
product spontaneously releases phenol by intramolecular cyclization and hydrolysis to a 
negatively charged, cell impermeable tenofovir-alanine intermediate (Balzarini et al., 1996). 
Formation of tenofovir-alanine is faster in resting PBMC compared to activated PBMC, 
while metabolism to parent tenofovir by a phosphoamidase and downstream 
phosphorylation to tenofovir-MP and tenofovir-DP is much faster in activated PBMC. A 
recent clinical study comparing 50 mg and 150 mg doses of GS-7340 with 300 mg TDF was 
conducted to determine the efficacy, safety and pharmacokinetics over 14 days (Markowitz 
et al., 2011). Viral loads were reduced -1.71-log and -1.57-log for 150 mg and 50 mg doses, 
respectively, compared to 0.94-log for TDF. PBMC levels of tenofovir were 4 – 33- times 
greater with GS-7340 than those for TDF at day 14 while plasma levels of tenofovir were 
decreased up to 88% at 24 hours with administration of GS-7340 compared to TDF. No 
serious adverse events were reported while the most frequent complaint was mild to 
moderate headache and nausea.  
4.5 CMX-157 
Like GS-7340, CMX-157 is an alternative prodrug of tenofovir designed to increase cell 
penetration by the natural lipid uptake pathways (Figure 9; Hostetler et al., 1997; Painter et 
al., 2004). CMX-157 contains a hexadecyloxypropyl (HDP) lipid conjugation which mimics 
lysophosphatidylcholine. CMX-157, unlike TDF is not cleaved to free tenofovir in the 
intestinal mucosa and thus circulates in plasma as the tenofovir-HDP lipid conjugate 
(Painter et al., 2007). Tenofovir-HDP is not a substrate for human organic anion transporters 
and therefore is subject to decreased renal excretion and increased intracellular drug 
exposure compared to TDF (Tippin et al., 2010). Free tenofovir is liberated intracellularly by 
hydrolytic removal of the HDP lipid by phospholipases. Intracellular activation to the active 
tenofovir-DP form is achieved in the same manner as TDF. CMX-157 delivers > 30-fold 
increased active metabolite tenofovir-DP in PBMC than tenofovir. Higher intracellular 
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concentrations of CMX-157 provide >300-fold greater activity against clinical isolates than 
tenofovir with EC50 values < 1 nM (Lanier et al., 2010). It has additionally been proposed 
that CMX-157 may bind cell free virions by direct lipid insertion into the viral envelope 
resulting in facilitated delivery to target cells (Painter et al., 2007). CMX-157 recently 
completed a Phase I clinical trial to evaluate safety, tolerability and pharmacokinetics. CMX-
157 was well tolerated with no drug-related adverse events. Plasma levels increased linearly 
with dose and active TFV-DP was detected up to six days post administration of a 400 mg 
dose suggesting the possibility of a once weekly dosing regimen.  
 
Fig. 9. Intracellular metabolism of GS-7340 and CMX-157  
5. Conclusions 
Nucleoside and nucleotide reverse transcriptase inhibitors have remained the backbone of 
antiretroviral therapy. The absolute dependence of NRTI on host cellular enzymes for 
activation is a unique property of this drug class.  The eight approved NRTI and numerous 
experimental NRTI display great diversity for all of these factors, thus presenting 
pharmacological advantages and challenges that are unique to the NRTI class. The complex 
relationships between NRTIs and host cell enzymes have necessitated detailed studies of the 
in vitro and in vivo pharmacologic properties of novel NRTIs in pre-clinical development. 
Current drug discovery efforts increasingly utilize NRTI prodrugs in order to accelerate 
NRTI phosphorylation or otherwise improve pharmacologic properties. Further 
understanding of the cellular pharmacology of NRTI is crucial for the development of novel 
drugs for increased potency, improved safety and tolerability, and decreased resistance. 
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